Stéphane Thiroloix

Our jellyfish collagen-based innovation addresses complex regenerative medical needs, shaping next generation treatments and supporting current and future scientific research. At the heart of our products is marine-sourced Collagen Type 0, an evolutionary ancient stem collagen that is foundational, allowing greater applications across multiple indications.

We surf, we sail, we paddle, we fish and we design what we wear : durable and timeless products, professionally manufactured in limited quantities by like-minded people. Our Ocean Stores are inspiring and welcoming, dedicated to our salted community and their way of life. To design and distribute clothing, equipment and products that are fit for ocean sports and life on their shores. To clothe, inspire and reconnect an international community of discerning, influential adults who have an emotional, sporting or professional relationship with the ocean. To use our economic and creative activity to stimulate and contribute to the rationalisation of our consumption patterns: Produce better and consume less, thicker, simpler, more repairable, more resistant, more sustainable.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.

Our jellyfish collagen-based innovation addresses complex regenerative medical needs, shaping next generation treatments and supporting current and future scientific research. At the heart of our products is marine-sourced Collagen Type 0, an evolutionary ancient stem collagen that is foundational, allowing greater applications across multiple indications.

AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making plans to expedite a Phase 3 trial. The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. In 2023, the company won France Biotech’s prestigious ESG HealthTech Trophy in recognition of its early commitment to ESG initiatives. For more information, see the company’s website

We surf, we sail, we paddle, we fish and we design what we wear : durable and timeless products, professionally manufactured in limited quantities by like-minded people. Our Ocean Stores are inspiring and welcoming, dedicated to our salted community and their way of life. To design and distribute clothing, equipment and products that are fit for ocean sports and life on their shores. To clothe, inspire and reconnect an international community of discerning, influential adults who have an emotional, sporting or professional relationship with the ocean. To use our economic and creative activity to stimulate and contribute to the rationalisation of our consumption patterns: Produce better and consume less, thicker, simpler, more repairable, more resistant, more sustainable.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.